Bleeding prevention in young athletes with hemophilia A

This study compares two preventive treatments for hemophilia A in young people who play sports: Emicizumab, a newer medication given as a shot under the skin once a week to once monthly, and factor VIII, a traditional treatment given intravenously (into a vein) several times a week. The study wants to understand how well each treatment prevents bleeding in young athletes and whether one is better suited for active sports participation.

Hemophilia A is a bleeding disorder that makes it hard for blood to clot, and while sports are encouraged for health and social reasons, they increase bleeding risk. Current preventive treatments require frequent infusions and don't completely stop bleeds, so researchers want to know if this newer medication—which is easier to give and stays in the body longer—can better protect young athletes during physical activity.